Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study

Oesophagogastric (OG) cancer is a highly lethal disease requiring novel treatment options. c-MYC and/or HER-2 amplified oesophageal cancer models have demonstrated sensitivity to BTK inhibition with ibrutinib. We evaluated the safety and efficacy of ibrutinib in patients with c-MYC and/or HER2 ampli...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Fiona Turkes, Annette Bryant, Ruwaida Begum, Michael Davidson, Eleftheria Kalaitzaki, Maria Aresu, Retchel Lazaro-Alcausi, Jane Bryant, Isma Rana, Sue Chua, Lauren Aronson, Sanna Hulkki-Wilson, Charlotte Fribbens, David Watkins, Sheela Rao, Naureen Starling, David Cunningham, Irene Y. Chong, Ian Chau
Materialtyp: Artigo
Språk:Inglês
Publicerad: MDPI AG 2022-03-01
Serie:Current Oncology
Ämnen:
oesophagogastric cancer
HER2
c-MYC
ibrutinib
Länkar:https://www.mdpi.com/1718-7729/29/4/176
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk